Fractyl Health, Inc. (NASDAQ:GUTS) Short Interest Update

Fractyl Health, Inc. (NASDAQ:GUTS) was the target of a significant drop in short interest in the month of March. As of March 13th, there was short interest totaling 5,831,445 shares, a drop of 55.7% from the February 26th total of 13,162,054 shares. Based on an average trading volume of 2,357,267 shares, the days-to-cover ratio is currently 2.5 days. Approximately 5.8% of the shares of the stock are short sold.

Key Stories Impacting Fractyl Health

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (notably FY2026–FY2030) and trimmed near‑term loss estimates while keeping a “Buy” rating and an $8.00 price target — this signals the analyst expects meaningful recovery and eventual profitability, supporting upside versus the current sub‑$1 trade. HC Wainwright analyst note (MarketBeat)
• Positive Sentiment: Canaccord Genuity reaffirmed a “Buy” rating and an $8.00 price target, echoing the bullish analyst narrative and providing additional third‑party validation of the longer‑term thesis. Canaccord reaffirmation (Benzinga)
• Neutral Sentiment: Q4 2025 earnings call transcript is available — the company recently reported an EPS beat for Q4 (reported EPS vs. consensus), which is supportive but investors will focus on follow‑up cadence, cash runway, and clinical/regulatory catalysts. Q4 2025 earnings call transcript (MSN)
• Negative Sentiment: TipRanks flagged “significant compliance risks” under global anti‑corruption and sanctions laws after a new risk disclosure — legal/compliance issues can slow partnerships, delay commercial progress, or increase remediation costs, creating downside risk and adding near‑term uncertainty. Compliance risk disclosure (TipRanks)

Institutional Investors Weigh In On Fractyl Health

A number of institutional investors and hedge funds have recently modified their holdings of GUTS. Virtu Financial LLC purchased a new stake in shares of Fractyl Health in the fourth quarter worth approximately $153,000. Susquehanna Portfolio Strategies LLC acquired a new position in Fractyl Health in the 4th quarter valued at approximately $108,000. Quadrature Capital Ltd lifted its position in Fractyl Health by 2,047.1% in the 4th quarter. Quadrature Capital Ltd now owns 290,714 shares of the company’s stock worth $640,000 after buying an additional 277,174 shares in the last quarter. Millennium Management LLC lifted its position in Fractyl Health by 356.6% in the 4th quarter. Millennium Management LLC now owns 1,861,418 shares of the company’s stock worth $4,095,000 after buying an additional 1,453,751 shares in the last quarter. Finally, Catalio Capital Management LP boosted its stake in shares of Fractyl Health by 5.3% during the 4th quarter. Catalio Capital Management LP now owns 5,491,866 shares of the company’s stock valued at $12,082,000 after buying an additional 277,630 shares during the period.

Wall Street Analysts Forecast Growth

GUTS has been the subject of a number of research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a research note on Thursday. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a research note on Tuesday, December 2nd. Morgan Stanley lowered Fractyl Health from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $8.00 to $2.00 in a report on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fractyl Health in a report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $5.40.

Fractyl Health Stock Performance

GUTS stock traded down $0.02 on Friday, hitting $0.45. 2,384,936 shares of the company’s stock traded hands, compared to its average volume of 2,680,174. Fractyl Health has a 1-year low of $0.38 and a 1-year high of $3.03. The company has a quick ratio of 4.27, a current ratio of 4.78 and a debt-to-equity ratio of 3.23. The stock has a fifty day moving average of $0.71 and a 200-day moving average of $1.28.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings results on Tuesday, March 24th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.34. On average, research analysts expect that Fractyl Health will post -1.61 EPS for the current year.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.